Psyched Wellness Submits a Provisional Patent Application for AME-1

Toronto, Ontario, March 17, 2021 – Psyched Wellness Ltd. (CSE:PSYC, OTCQB:PSYCF, FRANKFURT:5U9) (the “Company” or “Psyched”) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce the company has submitted a provisional patent application with the United States Patent and Trademark office, to cover the Company’s unique extraction processes for its proprietary Amanita muscaria extract AME-1.

The application was submitted on March 12, 2021 as App. No. 63/160,721, and discloses and claims muscimol extraction from Amanita mushrooms, and more particularly, enhanced muscimol extraction processes from Amanita muscaria, including by distillation and refluxing and/or pressing, resulting in a liquid or powder extract useful for preparations for human health.

“We have invested a lot of resources to develop AME-1 using a unique extraction protocol that we have developed,” said David Shisel COO of Psyched Wellness. “We believe that AME-1 has great potential and will be the foundation for many future products.”

Jeff Stevens, CEO of Psyched Wellness said, “Filing this provisional patent is a key milestone for PSYC and our shareholders. We recognize the patent frenzy that is taking place in the sector and although we are the only company (we are aware of) studying Amanita Muscaria and, specifically, Muscimol, it is critical to protect our work and our shareholders from others infringing on our intellectual property. I see this as the first of many provisional patents to come.”